SCHEMBL6293604

SCHEMBL6293604

CCOC(=O)C1=C(C(F)(F)F)Nc2n[nH]cc2C1c1ccc(C(=O)OCC)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
PDGFRB P09619 1/20 0.42
KDR P35968 1/20 0.42
ADORA2B P29275 4/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 2/20 0.41
ABCC1 P33527 1/20 0.40
GAA P10253 3/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39
ACHE P22303 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293641 0.91 ABCC1 (0.53) EGFRERBB2PDGFRBKDRADORA2B
SCHEMBL6292278 0.90 ADORA3 (0.47) EGFRERBB2PDGFRBKDRADORA2B
SCHEMBL6297295 0.90 ALDH1A1 (0.54) EGFRERBB2PDGFRBKDRADORA2B
SCHEMBL6296588 0.85 ADORA2B (0.58) ADORA2BALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL6296794 0.83 CACNA1B (0.52) ABCC1ACHE
SCHEMBL6293656 0.82 CACNA1C (0.52) ACHE
SCHEMBL6297236 0.82 MEN1 (0.44) ADORA2BALDH1A1TSHRHTTGAA
SCHEMBL6296647 0.81 GAA (0.49) ALDH1A1KDM4ESMN1; SMN2TSHRHTT
SCHEMBL6296549 0.81 PKM (0.45) ADORA2BALDH1A1KDM4ETSHRLMNA
SCHEMBL6296612 0.80 MAPT (0.48) ADORA2BHTTGAAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB EGFR 4751/4885ERBB2 3964/4885PDGFRB 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.